RxDoctor Payments Data

Heather Gaudard

Nurse Practitioner · Owosso, MINPI 1225524903

Payments from drug & device makers

$4,284in general payments, 2019–2025

Across 178 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$467
  • Johnson & Johnson$374
  • AbbVie$335
  • Medtronic$313
  • Convatec Inc.$244
  • Teleflex LLC$190
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,03194%
  • Education$2536%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,284 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

See all nurse practitioner providers in Michigan

Medicare billing

Part B allowed, 2024
$10,053
Medicare patients
105
Services billed
220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide11$152,588
GemtesaVibegron84$83,926
MyrbetriqMirabegron99$78,190
Mirabegron ErMirabegron18$9,062
Testosterone23$7,410
Tamsulosin Hcl258$5,195
Estradiol41$4,229
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl16$2,939
Trimethoprim33$2,555
Fosfomycin Tromethamine16$2,517
Cephalexin59$2,387
Fesoterodine Fumarate ErFesoterodine Fumarate23$2,349
Alfuzosin Hcl ErAlfuzosin Hcl49$1,564
Potassium Citrate ErPotassium Citrate14$1,049
Tolterodine Tartrate ErTolterodine Tartrate13$969

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$45$230,778110 claims
Sumitomo Pharma America, Inc.Gemtesa$173$83,92684 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.

Other nurse practitioner in Owosso

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →